Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction

Autor: Faiez Zannad, Laura Filipetti, Erwan Bozec, Masatake Kobayashi, Christine Selton-Suty, Stefano Coiro, Zohra Lamiral, Patrick Rossignol, João Pedro Ferreira, Nicolas Girerd, Olivier Huttin
Přispěvatelé: Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Division of Cardiology, University of Perugia, Ospedale S. Maria della Misericordia, The STANISLAS study was sponsored by Nancy CHRU and supported by a public grant overseen by the French National Research Agency (ANR) as part of the second ‘Investissements d'Avenir’ programme (reference: ANR‐15‐RHUS‐0004). The BioSE‐PreIC study was funded by the 'programme hospitalier de recherche clinique' (PHRCI 13‐084), ANR-15-RHUS-0004,FIGHT-HF,Combattre l'insuffisance cardiaque(2015), Università degli Studi di Perugia = University of Perugia (UNIPG), BOZEC, Erwan, Combattre l'insuffisance cardiaque - - FIGHT-HF2015 - ANR-15-RHUS-0004 - RHUS - VALID
Rok vydání: 2021
Předmět:
Male
Proteomics
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty
Short Communication
Short Communications
Diastole
Heart failure
030204 cardiovascular system & hematology
Doppler echocardiography
Left ventricular hypertrophy
03 medical and health sciences
Procollagen type III
0302 clinical medicine
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Internal medicine
Natriuretic Peptide
Brain
medicine
Humans
cardiovascular diseases
030212 general & internal medicine
Heart failure
diastolic
Ventricular Remodeling
medicine.diagnostic_test
business.industry
Systolic function
Doppler
Left ventricle
medicine.disease
Brain natriuretic peptide
Predictive value
Echocardiography
Doppler
[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
3. Good health
diastolic
lcsh:RC666-701
Echocardiography
Cohort
Cardiology
Female
Hypertrophy
Left Ventricular
Collagen
Cardiomyopathies
Cardiology and Cardiovascular Medicine
business
Biomarkers
Zdroj: ESC Heart Failure
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13203⟩
ESC Heart Failure, Vol 8, Iss 2, Pp 1700-1705 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13203⟩
ISSN: 2055-5822
DOI: 10.1002/ehf2.13203
Popis: International audience; Aims: Biomarkers reflecting myocardial fibrosis and inflammation have been individually associated with left ventricular hypertrophy (LVH) and diastolic dysfunction (DD). However, the added value of a fibrosis-inflammation multimarker approach in a populational setting is yet to be studied. We evaluated the value of a multimarker approach to detect LVH and DD in a large population-based cohort.Methods and results: In a prespecified analysis (BioSe-PreIC study) of the 4th visit of the STANISLAS cohort (1705 subjects, 47 ± 14 years, 47.4% men), we evaluated the ability of brain natriuretic peptide (BNP), Galectin-3 (GAL3), N-terminal propeptide of procollagen type III (P3NP), and soluble ST2 to predict LVH (LV mass > 116/100 g/m2 for men/women) and DD using discrimination (C-index) and reclassification analysis (NRI). Participants with LVH and/or DD had significantly higher levels of BNP, GAL3, and ST2. Overall, the predictive value of clinical variables for LVH and/or DD was good (C-index ranging from 0.76 to 0.82) and the addition of BNP, Gal3, P3NP, and ST2 moderately but significantly improved predictive value (delta C-index = 0.03, P = 0.03 for LVH and 0.01, P = 0.01 for DD) and reclassification (NRI = 25.3, P = 0.02 for LVH and NRI = 32.7 for DD, P < 0.0001). Gal3, P3NP, and ST2 significantly improved predictive value (delta C-index = 0.01, P = 0.01) and reclassification (NRI = 31.3, P < 0.0001) for DD of top of clinical variables and BNP.Conclusions: As the measurement of Gal3, P3NP, and ST2 results in marginal (even if significant) increase in the prediction of DD/LVH on top of routine evaluation, their systematic use should not be promoted in unselected healthy individuals to screen for preclinical DD. Further research is needed to determine whether a more personalized medicine approach combing proteomic and clinical scoring can amplify the added value of biomarkers to identify preclinical DD.
Databáze: OpenAIRE
Externí odkaz: